Area of research
Oncology · Hepatology
Research interest
Research focused on Cetuximab and Bevacizumab, with related work in Clinical endpoint, Fluorouracil, KRAS. Notable publications include 'Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii...', 'Quantitative Analyses of Early Tumor Shrinkage on Clinical Outcome in an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (Clime Study)', and '186P Bevacizumab in combination with 5-fluorouracil (5-FU) based doublet chemotherapy as neoadjuvant therapy for Chinese patients with previously untreated, unresectable...'.
186P Bevacizumab in combination with 5-fluorouracil (5-FU) based doublet chemotherapy as neoadjuvant therapy for Chinese patients with previously untreated, unresectable liver-only metastatic colorectal cancer: A multi-center, single-arm phase II study
Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (Clime Study)
Quantitative Analyses of Early Tumor Shrinkage on Clinical Outcome in an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (Clime Study)